PALSIDE

Palbociclib is a novel cyclin-dependent kinase (CDK) inhibitor that works by blocking the activity of CDK4 and CDK6, two enzymes that play a key role in cell division and proliferation. By inhibiting CDK4/6 activity, palbociclib can slow down or stop the growth of cancer cells, potentially leading to remission or extended survival.